he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
提示信源地址
编辑: jiang上一页:怎么准确检验癫痫病?
下一页:癫痫病检验的主要依据
- 2022-05-032017癫痫病的月所治疗方法是什么
- 2022-04-25青少年癫失眠与癫失眠的关系有哪些 不同年龄段失眠病的联系
- 2022-04-20隐源性癫痫发病率翻倍
- 2022-04-13高考食谱 吃对食物,实现高考梦(13)
- 2022-04-12验孕┃早孕试纸不准吗?为什么要做早孕检查?
- 2022-04-11抗癫痫药物预防新发癫痫:任重而道远
- 高考食谱 吃对食物,实现高考梦(13)
- 验孕┃早孕试纸不准吗?为什么要做早孕检查?
- 抗癫痫药物预防新发癫痫:任重而道远
- 癫痫治疗障碍仍难以克服
- 中华医学会系列精选指南|急性腹痛、淋巴瘤、银屑病的诊断和治疗
- 疾病新知:毛囊性白癜风
- FDA批准Aptiom用于治疗患者癫痫发作
- 17 年度经验:随访胡须斑秃预后
- 银屑病药物 Brodalumab 自杀倾向副作用AZ 遭受重创
- 特发性癫痫大发作药物治疗的首选
- 李敖病逝!面对医疗展示勇士的姿态
- AP&T:使用anti-TNFα治疗自身免疫性疾病的患者会增加患炎症性肠病的几率
- 儿童白癜风的原因是什么 儿童白癜风怎么办?
- spa中国有五个专业spa会所介绍
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 心房颤动和扑动心电图诊断要点
- 为什么身上有小白点 可能得了这种病?
- 白癜风病愈后如何巩固防复发?
- 有效缓解饮食小窍门
- 广西百色破获药案:涉及74家药店,3000多盒
- 综述:癫痫持续状态诊治最新进展
- CSP2016:李凌江教授谈论了与应激创伤障碍相关的问题
- 晚餐吃什么减肥?这样吃饭很容易减肥
- 屁股真的越翘越好吗?不良姿势造成危害,骨盆前倾需要纠正
- 运动或帮助保护1型糖尿病患者β细胞功能
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 黑芝麻的营养价值 吃黑芝麻的好处
- JPD:左旋多巴-治疗帕金森病的卡比多巴肠凝胶与生活质量和症状有什么关系?
- 于明治癫痫病能于明治的好么
- 20世纪癫痫病的症状都有什么
- 阿尔茨海默病或是进化特有疾病,同神经元及神经环路活性异常相关
- 癫痫病的头痛有哪些病因
- 太原癫痫病医院:想要快点控制病情,这3大诊疗误区你一定要发觉!
- 如何诊断孩童癫痫病
- LITT激光间质热疗如何扫除药物难治性癫痫?
- 北京天坛医院张教授入选“北京史学家”
- 癫痫病怎样治果会好
- 小儿癫痫病怎么鉴别治疗法病症
- 癫痫病较常见的成因是什么
- 抑郁症的症状是什么